Understanding the pathophysiological changes via untargeted metabolomics in COVID-19 patients.
COVID-19
LC/Q-TOF/MS
leukotriene D4
purinergic signaling
untargeted metabolomics
Journal
Journal of medical virology
ISSN: 1096-9071
Titre abrégé: J Med Virol
Pays: United States
ID NLM: 7705876
Informations de publication
Date de publication:
04 2021
04 2021
Historique:
received:
04
09
2020
revised:
02
12
2020
accepted:
03
12
2020
pubmed:
11
12
2020
medline:
20
3
2021
entrez:
10
12
2020
Statut:
ppublish
Résumé
Coronavirus disease 2019 (COVID-19) is an infectious respiratory disease caused by a new strain of the coronavirus. There is limited data on the pathogenesis and the cellular responses of COVID-19. In this study, we aimed to determine the variation of metabolites between healthy control and COVID-19 via the untargeted metabolomics method. Serum samples were obtained from 44 COVID-19 patients and 41 healthy controls. Untargeted metabolomics analyses were performed by the LC/Q-TOF/MS (liquid chromatography quadrupole time-of-flight mass spectrometry) method. Data acquisition, classification, and identification were achieved by the METLIN database and XCMS. Significant differences were determined between patients and healthy controls in terms of purine, glutamine, leukotriene D4 (LTD4), and glutathione metabolisms. Downregulations were determined in R-S lactoglutathione and glutamine. Upregulations were detected in hypoxanthine, inosine, and LTD4. Identified metabolites indicate roles for purine, glutamine, LTD4, and glutathione metabolisms in the pathogenesis of the COVID-19. The use of selective leukotriene D4 receptor antagonists, targeting purinergic signaling as a therapeutic approach and glutamine supplementation may decrease the severity and mortality of COVID-19.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2340-2349Informations de copyright
© 2020 Wiley Periodicals LLC.
Références
Paules CI, Marston HD, Fauci AS. Coronavirus infections-more than just the common cold. JAMA. 2020;323(8):707. https://doi.org/10.1001/jama.2020.0757
https://www.who.int/emergencies/diseases/novel-coronavirus-2019
Wu D, Wu T, Liu Q, Yang Z. The SARS-CoV-2 outbreak: what we know. Int J Infect Dis. 2020;94:44-48. https://doi.org/10.1016/j.ijid.2020.03.004
Harapan H, Itoh N, Yufika A, et al. Coronavirus disease 2019 (COVID-19): a literature review. J Infect Public Health. 2020;13(5):667-673. https://doi.org/10.1016/j.jiph.2020.03.019
Samavati L, Uhal BD. ACE2, much more than just a receptor for SARS-COV-2. Front Cell Infect Microbiol. 2020;10:317. https://doi.org/10.3389/fcimb.2020.00317
Coperchini F, Chiovato L, Croce L, Magri F, Rotondi M. The cytokine storm in COVID-19: an overview of the involvement of the chemokine/chemokine-receptor system. Cytokine Growth Factor Rev. 2020;53:25-32. https://doi.org/10.1016/j.cytogfr.2020.05.003
Bujak R, Struck-Lewicka W, Markuszewski MJ, Kaliszan R. Metabolomics for laboratory diagnostics. J Pharm Biomed Anal. 2015;113:108-120. https://doi.org/10.1016/j.jpba.2014.12.017
Wu D, Shu T, Yang X, et al. Plasma metabolomic and lipidomic alterations associated with COVID-19. Natl Sci Rev. 2020;7(7):1157-1168. https://doi.org/10.1093/nsr/nwaa086
Cui L, Zheng D, Lee YH, et al. Metabolomics investigation reveals metabolite mediators associated with acute lung injury and repair in a murine model of influenza pneumonia. Sci Rep. 2016;6(1):26076. https://doi.org/10.1038/srep26076
Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497-506. https://doi.org/10.1016/S0140-6736(20)30183-5
Le T-TT, Berg NK, Harting MT, Li X, Eltzschig HK, Yuan X. Purinergic signaling in pulmonary inflammation. Front Immunol. 2019;10:1633. https://doi.org/10.3389/fimmu.2019.01633
Yin J, Ren W, Huang X, Deng J, Li T, Yin Y. Potential mechanisms connecting purine metabolism and cancer therapy. Front Immunol. 2018;9:1697. https://doi.org/10.3389/fimmu.2018.01697
Fisher O, Benson RA, Imray CH. The clinical application of purine nucleosides as biomarkers of tissue Ischemia and hypoxia in humans in vivo. Biomark Med. 2019;13(11):953-964. https://doi.org/10.2217/bmm-2019-0049
del Castillo Velasco-Martínez I, Hernández-Camacho CJ, Méndez-Rodríguez LC, Zenteno-Savín T. Purine metabolism in response to hypoxic conditions associated with breath-hold diving and exercise in erythrocytes and plasma from bottlenose dolphins (Tursiops truncatus). Comp Biochem Physiol A Mol Integr Physiol. 2016;191:196-201. https://doi.org/10.1016/j.cbpa.2015.10.021
Saugstad OD. Hypoxanthine as an indicator of hypoxia: its role in health and disease through free radical production. Pediatr Res. 1988;23(2):143-150. https://doi.org/10.1203/00006450-198802000-00001
Liaudet L, Mabley JG, Pacher P, et al. Inosine exerts a broad range of antiinflammatory effects in a murine model of acute lung injury. Ann Surg. 2002;235(4):568-578. https://doi.org/10.1097/00000658-200204000-00016
Fredholm BB. Adenosine, an endogenous distress signal, modulates tissue damage and repair. Cell Death Differ. 2007;14(7):1315-1323. https://doi.org/10.1038/sj.cdd.4402132
Karmouty-Quintana H, Xia Y, Blackburn MR. Adenosine signaling during acute and chronic disease states. J Mol Med. 2013;91(2):173-181. https://doi.org/10.1007/s00109-013-0997-1
Armeni T, Cianfruglia L, Piva F, et al. S-d-Lactoylglutathione can be an alternative supply of mitochondrial glutathione. Free Radic Biol Med. 2014;67:451-459. https://doi.org/10.1016/j.freeradbiomed.2013.12.005
Wu G, Fang Y-Z, Yang S, Lupton JR, Turner ND. Glutathione metabolism and its implications for health. J Nutr. 2004;134(3):489-492. https://doi.org/10.1093/jn/134.3.489
Gaucher C, Boudier A, Bonetti J, Clarot I, Leroy P, Parent M. Glutathione: antioxidant properties dedicated to nanotechnologies. Antioxidants (Basel, Switzerland). 2018;7(5):62. https://doi.org/10.3390/antiox7050062
Lu SC. Glutathione synthesis. Biochim Biophys Acta. 2013;1830(5):3143-3153. https://doi.org/10.1016/j.bbagen.2012.09.008
Lin C-W, Lin K-H, Hsieh T-H, Shiu S-Y, Li J-Y. Severe acute respiratory syndrome coronavirus 3C-like protease-induced apoptosis. FEMS Immunol Med Microbiol. 2006;46(3):375-380. https://doi.org/10.1111/j.1574-695X.2006.00045.x
den Brand JMA, Haagmans BL, van Riel D, Osterhaus ADME, Kuiken T. The pathology and pathogenesis of experimental severe acute respiratory syndrome and influenza in animal models. J Comp Pathol. 2014;151(1):83-112. https://doi.org/10.1016/j.jcpa.2014.01.004
Peters-Golden M, Henderson WR. Leukotrienes. N Engl J Med. 2007;357(18):1841-1854. https://doi.org/10.1056/NEJMra071371
Funk CD, Ardakani A. A novel strategy to mitigate the hyperinflammatory response to COVID-19 by targeting leukotrienes. Front Pharmacol. 2020;11:1214. https://doi.org/10.3389/fphar.2020.01214
Hammarstrom S. Leukotrienes. Annu Rev Biochem. 1983;52(1):355-377. https://doi.org/10.1146/annurev.bi.52.070183.002035
Miyata J, Fukunaga K, Kawashima Y, Ohara O, Arita M. Cysteinyl leukotriene metabolism of human eosinophils in allergic disease. Allergol Int. 2020;69(1):28-34. https://doi.org/10.1016/j.alit.2019.06.002
Murphy RC, Gijón MA. Biosynthesis and metabolism of leukotrienes. Biochem J. 2007;405(3):379-395. https://doi.org/10.1042/BJ20070289
Hoxha M, Lewis-Mikhael A-M, Bueno-Cavanillas A. Potential role of leukotriene receptor antagonists in reducing cardiovascular and cerbrovascular risk: a systematic review of human clinical trials and in vivo animal studies. Biomed Pharmacother. 2018;106:956-965. https://doi.org/10.1016/j.biopha.2018.07.033
Peters-Golden M, Gleason MM, Togias A. Cysteinyl leukotrienes: multi-functional mediators in allergic rhinitis. Clin Exp Allergy. 2006;36(6):689-703. https://doi.org/10.1111/j.1365-2222.2006.02498.x
Mangalmurti N, Hunter CA. Cytokine storms: understanding COVID-19. Immunity. 2020;53(1):19-25. https://doi.org/10.1016/j.immuni.2020.06.017
Fidan C, Aydoğdu A. As a potential treatment of COVID-19: Montelukast. Med Hypotheses. 2020;142:109828. https://doi.org/10.1016/j.mehy.2020.109828
Shen B, Yi X, Sun Y, et al. Proteomic and metabolomic characterization of COVID-19 patient sera. Cell. 2020;182(1):59-72. https://doi.org/10.1016/j.cell.2020.05.032
Cruzat V, Macedo Rogero M, Noel Keane K, Curi R, Newsholme P. Glutamine: metabolism and immune function, supplementation and clinical translation. Nutrients. 2018;10(11):1564. https://doi.org/10.3390/nu10111564
Oliveira G, de Abreu M, Pelosi P, Rocco P. Exogenous glutamine in respiratory diseases: myth or reality? Nutrients. 2016;8(2):76. https://doi.org/10.3390/nu8020076
Singleton KD, Serkova N, Beckey VE, Wischmeyer PE. Glutamine attenuates lung injury and improves survival after sepsis: role of enhanced heat shock protein expression. Crit Care Med. 2005;33(6):1206-1213. https://doi.org/10.1097/01.CCM.0000166357.10996.8A
Shih Y-M, Shih J-M, Pai M-H, Hou Y-C, Yeh C-L, Yeh S-L. Glutamine administration after sublethal lower limb ischemia reduces inflammatory reaction and offers organ protection in ischemia/reperfusion injury. J Parenter Enter Nutr. 2016;40(8):1122-1130. https://doi.org/10.1177/0148607115587949
Durante W. The emerging role of l-glutamine in cardiovascular health and disease. Nutrients. 2019;11(9):2092. https://doi.org/10.3390/nu11092092
Wischmeyer PE, Dhaliwal R, McCall M, Ziegler TR, Heyland DK. Parenteral glutamine supplementation in critical illness: a systematic review. Crit Care. 2014;18(2):R76. https://doi.org/10.1186/cc13836
Cengiz M, Borku Uysal B, Ikitimur H, et al. Effect of oral l-Glutamine supplementation on Covid-19 treatment. Clin Nutr Exp. 2020;33:24-31. https://doi.org/10.1016/j.yclnex.2020.07.003